Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 14,960 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Completed Phase 2 Interventional

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

NCT00003125
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ALVAC-CEA vaccine, aldesleukin, sargramostim, vaccinia-CEA vaccine
Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00057876
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
228
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Fresno, California + 164 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

NCT00412750
View directory record Official record
Conditions
Hepatitis B
Interventions
Telbivudine (LdT), peginterferon alpha-2a
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Impact of a Novel Patient Educational Booklet on Colonoscopy Quality

NCT00975247
View directory record Official record
Conditions
Colon Cancer, Colonoscopy
Interventions
Receiving an educational booklet
Other
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
56
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

NCT05552755
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
REC-4881, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

NCT03602885
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
Interventions
Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 28, 2026, 10:11 AM EDT
Not listed No phase listed Observational

Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy

NCT03626350
View directory record Official record
Conditions
Gastrointestinal Neoplasia, Hirschsprung's Disease, Esophageal Obstruction, Gastroparesis, Spastic Esophageal Disorders, Zenker's Diverticulum
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
250 participants
Timeline
2018 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674
View directory record Official record
Conditions
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions
NX-1607, Paclitaxel
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

NCT07677358
View directory record Official record
Conditions
Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
Interventions
Atirmociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Terminated No phase listed Observational

Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry

NCT06052358
View directory record Official record
Conditions
Atrial Fibrillation, GI Bleeding
Interventions
LAAC with Watchman FLX device
Device
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Overland Park, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 28, 2026, 10:11 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Rapid HCV RNA Testing and LInkage to Care

NCT04302948
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
HCV RNA screening
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 28, 2026, 10:11 AM EDT
Not listed Phase 1 Interventional

The Gut-Brain Study

NCT03426826
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Gastro-Intestinal Disorder
Interventions
FMT versus placebo
Biological
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional

Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection

NCT02523443
View directory record Official record
Conditions
Liver Cancer, Pain Management
Interventions
IV PCA, PCEA
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Active, not recruiting Phase 2 Interventional

Use of Antibiotic Irrigation to Decrease Wound Infections in Pediatric Perforated Appendicitis

NCT04039750
View directory record Official record
Conditions
Perforated Appendicitis
Interventions
antibiotic rinse with suction, suction only
Drug · Procedure
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
0 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed No phase listed Observational

A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer

NCT01986738
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Standard Radiation Therapy, Active Breathing Control Device (ABC), Computed Tomography Scan (CT)
Radiation · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

NCT01624285
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
sorafenib tosylate, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

NCT07681076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Trimethobenzamide, Ondansetron, Meclizine
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

NCT00674440
View directory record Official record
Conditions
Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy, CHI, PHHI
Interventions
F-DOPA, PET scan
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 4 Interventional Results available

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

NCT01285050
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 28, 2026, 10:11 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach

NCT07781774
View directory record Official record
Conditions
Colorectal Cancer (CRC) Screening, CRC Screening, Rectal Cancer, Colon Cancer, Colorectal Cancer
Interventions
Colorectal Cancer Education Materials, Cologuard test kit, Fecal immunochemical test kit, Usual Care
Behavioral · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

NCT07165132
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor, Somatostatin Receptor
Interventions
RYZ401
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
12
States / cities
Phoenix, Arizona • Jacksonville, Florida • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00098787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, Oxaliplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
110
States / cities
Greenbrae, California • Aurora, Colorado • Boulder, Colorado + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493
View directory record Official record
Conditions
Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
AZD5863, AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:11 AM EDT